Abstract
The treatment strategy for management of Burkitt lymphoma (BL) has evolved during the past decades and the clinical outcome for this disease as a whole has also improved. Due to limited information reported on survival trends of patients with stage I/II (limited‐stage) BL, here we used the Surveillance, Epidemiology, and End Results (SEER) database to conduct our study. The time period was divided into two eras (1983‐2001 and 2002‐2014) as the recent era reflected more intensive chemotherapy regimens, the availability of rituximab, the widespread use of antiretroviral therapy (ART) and improvements in supportive care. Patients with limited‐stage BL had a significantly better 5‐year overall survival (OS) in the 2002‐2014 era in both univariate analysis and multivariate analysis, compared with those in the 1983‐2001 era (64.1% vs 57.4%). However, clinical outcomes of elderly patients (≥60 years) and children patients (0‐19 years) did not significantly improve. Older age and race of black were correlated with poorer OS in multivariate analysis, whereas sex, primary sites, and application of radiotherapy did not significantly influence OS. In conclusion, the prognosis of patients with limited‐stage BL has improved in the 2002‐2014 era, but the outcome was still much poorer in elderly patients, which needs to be improved by identifying newly molecular‐targeted drugs and developing novel personalized therapeutic approaches.
Highlights
Burkitt lymphoma (BL) is a highly aggressive B‐cell non‐ Hodgkin lymphoma (NHL) characterized by the translocation and deregulation of the MYC gene on chromosome 8
We aimed to provide a better understanding of trends in survival of patients with stage I/ II BL in the United States, through using the Surveillance, Epidemiology, and End Results (SEER) database
A total of 1929 patients with stage I/II BL from the SEER database were included in this study, 539 (27.9%) in the 1983‐2001 era and 1390 (72.1%) in the 2002‐2014 era
Summary
Burkitt lymphoma (BL) is a highly aggressive B‐cell non‐ Hodgkin lymphoma (NHL) characterized by the translocation and deregulation of the MYC gene on chromosome 8. There is a small subset of BL presents in stage I and II (limited stage) and this small population has a better outcome than those with advanced stage.[20] The outcome of patients with advanced stage has improved[21] in the recent era owing to the use of more intense chemotherapy regimens,[7,8,9,10] the availability of rituximab,[7,12,14,16,17,22,23,24,25,26,27,28,29,30] the application of antiretroviral therapy (ART),[31] and improvements in supportive care.[9,10] it is unclear whether the recent changes in management modalities have affected the survival of limited‐stage BL patients who already had excellent cure rates. We aimed to determine the survival trends of different patient groups and identify factors that influenced the prognosis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
